These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer. Becze E ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750 [No Abstract] [Full Text] [Related]
25. Immune-boosting prostate cancer vaccine endorsed by FDA advisors. McBride D ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780 [No Abstract] [Full Text] [Related]
26. Searching for the ideal cancer vaccine. Cancer Biol Ther; 2009 Jan; 8(2):104-5. PubMed ID: 19263513 [No Abstract] [Full Text] [Related]
28. Continuous improvement versus innovation: the case for sipuleucel-T. Tombal B Eur Urol; 2012 Apr; 61(4):648-9; discussion 650-1. PubMed ID: 22154024 [No Abstract] [Full Text] [Related]
29. Approval of provenge seen as first step for cancer treatment vaccines. Brower V J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267 [No Abstract] [Full Text] [Related]
30. Is Provenge Angst a symbol or symptom of the times? Holcombe DG Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274 [No Abstract] [Full Text] [Related]
31. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. McKarney I Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575 [TBL] [Abstract][Full Text] [Related]
32. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer? Moyad MA Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606 [TBL] [Abstract][Full Text] [Related]
33. Prostate cancer treatment: the times they are a' changin'. Kirby R; Challacombe B; Dasgupta P; Fitzpatrick JM BJU Int; 2012 Nov; 110(10):1408-11. PubMed ID: 22937730 [No Abstract] [Full Text] [Related]
34. Cancer immunotherapy. White RL; Amin A Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920 [TBL] [Abstract][Full Text] [Related]